The baseline: about 47 novel drugs a year
[Chart: FDA CDER, New Drug Therapy Approvals 2025 (2016-2025); FDA Novel Drug Approvals for 2026 (to 20 Oct 2026). See the live document for the chart.]
FDA’s drug center (CDER) averaged about 47 novel approvals a year from 2016 to 2025, according to its 2025 annual report. The count swings widely, from 22 in 2016 to 59 in 2018, so a single year says little. By 20 October 2026, CDER had already approved 47, and December is usually busy (2025 had seven approvals in December alone). A simple extension of the 2026 pace points to the mid-to-high 50s for the full year; that is our estimate, not an FDA figure.
Note: FDA’s 2025 report charts 2023 as 54 approvals, while earlier counts said 55. We use the 2025 report’s figures.
Leading indicators: more companies, a flat pipeline, cautious money
Biotech startups now drive most approvals.
- BIO reports that emerging biotechs were behind 36 of 54 novel US approvals in 2024, about two-thirds. That count includes biologics approved by FDA’s biologics center.
- They also run 55% of clinical programs.
- The IQVIA Institute found that emerging biopharma originated 55% of novel active substances over the decade to 2021.
The number of drug developers keeps rising.
| Indicator | Earlier | Latest | Source |
|---|---|---|---|
| Drug R&D companies worldwide | 2,207 (2010) | 6,823 (2025); 7,057 (2026, +3.4%) | BIO; Citeline via SCI |
| Drugs in the global pipeline | about 23,900 (2025, implied by the 3.9% fall) | 22,940 (2026, -3.9%) | Citeline |
| New drug candidates entering the pipeline | 4,546 (2024) | 4,488 (2025) | Citeline via SCI |
| US share of R&D companies | 39% | 41% | Citeline via SCI |
| China share of R&D companies | 17% | 19% | Citeline via SCI |
Company growth is slowing: +11.4% in 2025, +3.4% in 2026. Citeline says the pipeline has been “fairly flat” for a few years, and part of the 2026 drop reflects a change in data collection. More companies are sharing a pipeline that is not growing.
Venture money favors late-stage assets.
- PitchBook counts $33.8 billion of biopharma venture funding in 2025, across 1,171 deals, up from $31.9 billion in 2024.
- Only about 32% went to early-stage companies, against more than 40% in 2020 to 2022. PitchBook says this points to “a meaningful reduction” in new company formations.
- J.P. Morgan counts $23.9 billion across 385 rounds through Q3 2026.
Late-stage money supports approvals in the next few years. Fewer first financings today mean fewer programs reaching FDA around the end of the decade.
China is a growing source of molecules. China’s share of pharma R&D rose to 31.1% in 2026, and IQVIA counts 30 novel active substances launched only in China in 2025. Some of these could later reach FDA through licensing deals, which would add to US approvals.
Forecast: 2026 to 2030
[Chart: Actuals: FDA CDER. Forecast: AskDona editorial estimate, October 2026. See the live document for the chart.]
How we built it. We started from the 2016 to 2025 average of about 47 a year. We then adjusted each year for the indicators above. These are judgment calls, not a statistical model.
| Scenario | 2027 to 2030 per year | What has to happen |
|---|---|---|
| Low | 40 to 44 | Review delays persist after the 2025 staff cuts, and the drop in early-stage funding cuts late-decade filings |
| Base | 50 to 52 | More developers, especially startups, keep filings slightly above the 10-year average. National priority vouchers add a few fast approvals. A flat pipeline caps the upside, and the early-stage squeeze trims 2029 to 2030 |
| High | 60 to 63 | The voucher program scales up, more China-originated assets are licensed and filed in the US, and the 2026 pace holds |
Why startups do not simply mean more approvals. The number of drug developers more than tripled from 2010 to 2025, but annual approvals stayed in the same 40 to 60 range. More companies mostly split the same pipeline into smaller pieces. The share of approvals going to emerging biotechs rises faster than the total.
What would change our view:
- the full-year 2026 count
- PDUFA VIII goals for applications from October 2027
- whether early-stage funding recovers in 2026 and 2027
Risks to the forecast
- FDA capacity. Staff cuts in 2025 have already slowed some actions.
- Policy changes. These include PDUFA VIII, the voucher pilot’s future, and how FDA handles accelerated approvals.
- Counting differences. CDER counts exclude biologics reviewed by FDA’s biologics center (CBER), such as most cell and gene therapies, so other sources report higher totals.
- Lumpy years. Single years have ranged from 22 to 59.
Using this forecast in AI and RAG
- Index FDA’s annual reports and the live approvals page as the ground truth for counts.
- Store each indicator with its source and date, such as company counts, pipeline size, and funding. Different sources count differently.
- Label every forecast figure as an estimate, with the scenario it belongs to.
- Refresh each January, when FDA publishes the prior year’s report.
Common mistakes
- Treating more startups as a one-for-one rise in approvals.
- Mixing CDER-only counts with CDER plus CBER totals.
- Extrapolating one strong year.
- Comparing funding figures from different trackers as if they were one series.
Checklist
- Counts tied to FDA reports
- CDER and CBER kept separate
- Indicator sources and dates recorded
- Scenario labels on all estimates
- Annual refresh scheduled
How AskDona helps
AskDona checks your market models and board materials against the FDA reports and industry data you load. It shows which figure each assumption rests on, and flags numbers that have no source.
Run a sample approval forecast evidence check
AskDona shows the evidence; your strategy and regulatory teams decide.
Editor’s note. This article is general information, not investment advice. Historical counts come from FDA. Indicator data comes from BIO, Citeline, IQVIA, PitchBook, and J.P. Morgan. The forecast is our own estimate as of 30 October 2026.
FAQ
How many novel drugs does FDA approve a year? CDER averaged about 47 a year from 2016 to 2025.
How many in 2026? CDER had approved 47 by 20 October 2026. We expect the mid-to-high 50s for the full year.
Will more biotech startups mean more approvals? Only modestly. Startups already account for about two-thirds of approvals, but the overall pipeline is flat. Our base case is about 50 to 52 a year to 2030.
What could push approvals higher? A larger voucher program, more licensed assets from China, and a recovery in early-stage funding.
References
All pages opened and checked by October 30, 2026.
| Source | What it supports |
|---|---|
| FDA: New Drug Therapy Approvals 2025 (PDF) | 2016 to 2025 counts, 2025 details |
| FDA: Novel Drug Approvals for 2026 | 47 approvals to 20 Oct 2026 |
| RAPS: CDER approved 46 novel drugs in 2025 | December 2025 approvals |
| BIO: State of Emerging Biotech Companies (PDF, Jun 2025) | Two-thirds of 2024 approvals, company counts |
| IQVIA: Emerging Biopharma’s Contribution to Innovation | 55% of novel active substances |
| IQVIA: Global R&D Trends 2026 | 2025 launches, China-only launches |
| SCI: Pharma R&D pipeline (2026) | Citeline company and pipeline counts |
| Fierce Biotech: Pipeline shrinks | 22,940 drugs, flat pipeline |
| BioSpace: PitchBook 2025 biotech VC | $33.8B, early-stage share |
| J.P. Morgan: Q3 2026 deal reports | $23.9B through Q3 2026 |
| FDA: CNPV pilot | 1 to 2 month review target |